drugset / Trial / NCT01739647
A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects
RandomizedParallel-groupDouble-blindBasic science
Summary
This is a single dose study in healthy male and female (of non-child bearing potential) volunteers, to assess the safety, effects on the body, and blood and urine drug levels of AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease
Timeline
- Start
- 2012-12
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanabecestat | Small molecule | 1 mg | Oral |
| Subject | Lanabecestat | Small molecule | 1000 mg | Oral |
Indications
No indication recorded.